公司盈利情况 - 公司自成立以来一直有重大经营亏损，预计未来仍会有大量亏损且可能无法实现盈利[19] 公司资金状况 - 截至2021年6月30日和2020年12月31日，公司现金及现金等价物分别为273,057千美元和213,119千美元[34] - 公司目前没有产品收入，依赖其他渠道筹集资金，如未来的债务或股权发行[234] - 公司认为其现金及现金等价物不存在重大违约或流动性风险，但不能保证未来投资不受市场价值不利变化的影响[233] 公司产品业务风险 - 公司在短期内依赖BXCL501和BXCL701的成功，若无法完成临床开发、获得营销批准或成功商业化，业务将受到重大损害[20] - 公司的产品候选药物可能会产生不良副作用，从而延迟或阻止其获得监管批准[23] 公司业务依赖情况 - 公司依赖BioXcel LLC提供某些业务服务[28] - 公司严重依赖第三方制造临床和商业供应的产品候选药物，若第三方制造商出现问题，产品开发和商业化可能会受阻[29] - 公司若无法找到第三方合作伙伴协助或分担产品开发成本，业务、财务状况和经营成果将受到重大损害[30] 公司专利保护 - 公司难以保护其专有权利，若专利无法充分保护产品候选药物，业务可能会受到损害[30]

April 2021 NASDAQ: BTAI | --- | --- | --- | --- | --- | |--------------------------------------------------------------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | Developing Transformative Medicines Utilizing AI Approaches | | | | | | May 2021 | | | | | | | | | | | Forward-Looking Statements This presentation includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this presentation ...

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q1 2021 Earnings Conference Call May 10, 2021 8:30 AM ET Company Participants Vimal Mehta - Chief Executive Officer Richard Steinhart - Chief Financial Officer Will Kane - Chief Commercial Officer Frank Yocca - Chief Scientific Officer Vince O’Neill - Chief Medical Officer Reina Benabou - Chief Development Officer Conference Call Participants Greg Harrison - Bank of America Suzana Princy - Goldman Sachs Brian Mills - Jefferies Sumant Kulkarni - Canaccord Robyn Karnau ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to | --- | --- | --- | |-------------------------------------------------------------------------------------------------|------------------ ...

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q4 2020 Earnings Conference Call March 11, 2021 8:30 AM ET Company Participants Vimal Mehta - Chief Executive Officer Richard Steinhart - Chief Financial Officer Will Kane - Chief Commercial Officer Frank Yocca - Chief Scientific Officer Vince O’Neill - Chief Medical Officer Reina Benabou - Chief Development Officer Conference Call Participants Geoff Meacham - Bank of America Graig Suvannavejh - Goldman Sachs Chris Howerton - Jefferies Sumant Kulkarni - Canaccord Rob ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark one) ⌧ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the year ended December 31, 2020 or ◻ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission file number 001-38410 BioXcel Therapeutics, Inc. (Exact name of Registrant as specified in its charter) | --- | --- | --- | --- | --- | ...

NASDAQ: BTAI | --- | --- | --- | --- | --- | --- | |----------------------------------------------------------------------------------------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | Developing and Commercializing Innovative Medicines Discovered using AI November 2020 | | | | | | | | | | | | | | | | | | | | Forward-Looking Statements This presentation includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking ...

Call Start: 08:30 January 1, 0000 9:10 AM ET BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q3 2020 Earnings Conference Call November 12, 2020 08:30 ET Company Participants Vimal Mehta - Chief Executive Officer Richard Steinhart - Chief Financial Officer Will Kane - Chief Commercial Officer Reina Benabou - Chief Development Officer Vince O'Neill - Chief Medical Officer Robert Risinger - Senior Vice President of Clinical Development Frank Yocca - Chief Scientific Officer Conference Call Participants Geoff Meacham ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38410 BioXcel Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 82-13867 ...

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q2 2020 Earnings Conference Call August 14, 2020 8:30 AM ET Company Participants Vimal Mehta – Chief Executive Officer Michael Stanton – Controller Rob Risinger – Senior Vice President-Clinical Development Will Kane – Chief Commercial Officer Reina Benabou – Chief Development Officer Conference Call Participants Geoff Meacham – Bank of America Robyn Karnauskas – Truist Securities Yatin Suneja – Guggenheim Partners Sumant Kulkarni – Canaccord Ram Selvaraju – H.C. Wain ...